Safety & Physician Supervision
Why Physician Supervision Matters for Peptide and Hormone Therapy
Peptide and hormone therapies require medical evaluation, lab screening, and ongoing monitoring to balance benefits against potential risks.
Public guidance from the FDA and NIH emphasizes that prescription therapies — including compounded peptides — should be initiated only after appropriate evaluation. Lab screening helps establish a baseline and surface contraindications.
Ongoing monitoring allows clinicians to adjust protocols, identify side effects early, and discontinue therapy when appropriate. This is the standard SEIVA follows for every protocol.
Key takeaways
- Baseline labs reduce risk before therapy.
- Ongoing monitoring is part of safe care.
- Compounded therapies are still prescription medicine.
Educational only. Not medical advice. SEIVA protocols are prescribed only after physician review and telehealth consultation.